StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Core SG&A expense by Year

Core SG&A expense ($M) ($M)

AstraZeneca Core SG&A expense: -$15,534M in FY2025, up 3.4% from a year earlier.

Latest, FY2025
-15,534
Period ended Dec 31, 2025
Change on a year earlier
+3.4%
-15,028 in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below

Where the FY2025 figure comes from

“|| SG&A expense | (19,933) | 209 | 4,059 | 131 | (15,534) | 3 | 3”

Source: Form 6-K FY2025Q4 Earnings Release ↗

Reported in Form 6-K Quarterly & Form 20-F Reported-to-Core Reconciliation.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCore SG&A expense ($M) ($M)Year on yearSource
FY2025Dec 31, 2025-15,534+3.4%Form 6-K FY2025Q4 Earnings Release ↗
FY2024Dec 31, 2024-15,028+9.4%Form 6-K FY2024Q4 Earnings Release ↗
FY2023Dec 31, 2023-13,739+7.1%Form 6-K FY2023Q4 Earnings Release ↗
FY2022Dec 31, 2022-12,826+15.5%Form 6-K FY2022Q4 Earnings Release ↗
FY2021Dec 31, 2021-11,104+18.6%Form 6-K FY2021Q4 Earnings Release ↗
FY2020Dec 31, 2020-9,362–Form 6-K FY2020Q4 Earnings Release ↗

Breakdown

What makes up core SG&A expense

Cite this data

StockData. (2026). AstraZeneca Core SG&A expense ($M), annual FY2020–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/core-sga

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.